CLAIMS

1. A compound of formula (I)



(I)

wherein:

R^1 is selected from C_{1-5} alkyl, C_{2-5} alkenyl, benzyl, -(C_{0-4} alkylene)-CN, and -(C_{1-4} alkylene)-COOH, and R^5 is a group R^{5A};

R^2 is hydrogen;

ring A is phenyl which is fused to the ring containing -CO-NR^2-;

each R^3 is independently halogen or C_{1-5} haloalkyl;

n is an integer of 0 to 4;

one of the ring atoms Z^1, Z^2 and Z^3 is C(-R^6) or N, and the other two of said rig atoms are each C(-R^6);

R^4 is selected from hydrogen, C_{1-5} alkyl, C_{2-5} alkenyl, C_{2-5} alkynyl, -(C_{0-4} alkylene)-OH, -(C_{0-4} alkylene)-O(C_{1-5} alkyl), -(C_{0-4} alkylene)-O(C_{1-5} alkylene)-OH, -(C_{0-4} alkylene)-O(C_{1-5} alkylene)-O(C_{1-5} alkyl), -(C_{0-4} alkylene)-SH, -(C_{0-4} alkylene)-S(C_{1-5} alkyl), -(C_{0-4} alkylene)-NH_2, -(C_{0-4} alkylene)-NH(C_{1-5} alkyl), -(C_{0-4} alkylene)-N(C_{1-5} alkyl)(C_{1-5} alkyl), -(C_{0-4} alkylene)-NH-OH, -(C_{0-4} alkylene)-N(C_{1-5} alkyl)-OH, -(C_{0-4} alkylene)-NH-O(C_{1-5} alkyl), -(C_{0-4} alkylene)-N(C_{1-5} alkyl)-O(C_{1-5} alkyl), halogen, C_{1-5} haloalkyl, -(C_{0-4}

alkylene)-O-(C_{1-5} haloalkyl), -(C_{0-4} alkylene)-CN, -(C_{0-4} alkylene)-CHO, -(C_{0-4} alkylene)-CO-(C_{1-5} alkyl), -(C_{0-4} alkylene)-COOH, -(C_{0-4} alkylene)-CO-O-(C_{1-5} alkyl), -(C_{0-4} alkylene)-O-CO-(C_{1-5} alkyl), -(C_{0-4} alkylene)-CO-NH_2, -(C_{0-4} alkylene)-CO-NH(C_{1-5} alkyl), -(C_{0-4} alkylene)-CO-N(C_{1-5} alkyl)(C_{1-5} alkyl), -(C_{0-4} alkylene)-NH-CO-(C_{1-5} alkyl), -(C_{0-4} alkylene)-N(C_{1-5} alkyl)-CO-(C_{1-5} alkyl), -(C_{0-4} alkylene)-NH-CO-O-(C_{1-5} alkyl), -(C_{0-4} alkylene)-N(C_{1-5} alkyl)-CO-O-(C_{1-5} alkyl), -(C_{0-4} alkylene)-O-CO-NH-(C_{1-5} alkyl), -(C_{0-4} alkylene)-O-CO-N(C_{1-5} alkyl)-(C_{1-5} alkyl), -(C_{0-4} alkylene)-SO_2-NH_2, -(C_{0-4} alkylene)-SO_2-NH(C_{1-5} alkyl), -(C_{0-4} alkylene)-SO_2-N(C_{1-5} alkyl)(C_{1-5} alkyl), -(C_{0-4} alkylene)-NH-SO_2-(C_{1-5} alkyl), -(C_{0-4} alkylene)-N(C_{1-5} alkyl)-SO_2-(C_{1-5} alkyl), -(C_{0-4} alkylene)-SO_2-(C_{1-5} alkyl), -(C_{0-4} alkylene)-SO-(C_{1-5} alkyl), -(C_{0-4} alkylene)-carbocyclyl, and -(C_{0-4} alkylene)-heterocyclyl, wherein the carbocyclyl moiety in said -(C_{0-4} alkylene)-carbocyclyl and the heterocyclyl moiety in said -(C_{0-4} alkylene)-heterocyclyl are each optionally substituted with one or more groups R^{Cyc};

R^{5A} is selected from -OH, and -O(C_{1-5} alkyl);

each R^6 is independently selected from hydrogen, C_{1-5} alkyl, C_{2-5} alkenyl, C_{2-5} alkynyl, -(C_{0-4} alkylene)-OH, -(C_{0-4} alkylene)-O(C_{1-5} alkyl), -(C_{0-4} alkylene)-O(C_{1-5} alkylene)-OH, -(C_{0-4} alkylene)-O(C_{1-5} alkylene)-O(C_{1-5} alkyl), -(C_{0-4} alkylene)-SH, -(C_{0-4} alkylene)-S(C_{1-5} alkyl), -(C_{0-4} alkylene)-NH_2, -(C_{0-4} alkylene)-NH(C_{1-5} alkyl), -(C_{0-4} alkylene)-N(C_{1-5} alkyl)(C_{1-5} alkyl), -(C_{0-4} alkylene)-NH-OH, -(C_{0-4} alkylene)-N(C_{1-5} alkyl)-OH, -(C_{0-4} alkylene)-NH-O(C_{1-5} alkyl), -(C_{0-4} alkylene)-N(C_{1-5} alkyl)-O(C_{1-5} alkyl), halogen, C_{1-5} haloalkyl, -(C_{0-4} alkylene)-O-(C_{1-5} haloalkyl), -(C_{0-4} alkylene)-CN, -(C_{0-4} alkylene)-CHO, -(C_{0-4} alkylene)-CO-(C_{1-5} alkyl), -(C_{0-4} alkylene)-COOH, -(C_{0-4} alkylene)-CO-O-(C_{1-5} alkyl), -(C_{0-4} alkylene)-O-CO-(C_{1-5} alkyl), -(C_{0-4} alkylene)-CO-NH_2, -(C_{0-4} alkylene)-CO-NH(C_{1-5} alkyl), -(C_{0-4} alkylene)-CO-N(C_{1-5} alkyl)(C_{1-5} alkyl), -(C_{0-4} alkylene)-NH-CO-(C_{1-5} alkyl), -(C_{0-4} alkylene)-N(C_{1-5} alkyl)-CO-(C_{1-5} alkyl), -(C_{0-4} alkylene)-NH-CO-O-(C_{1-5} alkyl), -(C_{0-4} alkylene)-N(C_{1-5} alkyl)-CO-O-(C_{1-5} alkyl), -(C_{0-4} alkylene)-O-CO-NH-(C_{1-5} alkyl), -(C_{0-4} alkylene)-O-CO-N(C_{1-5} alkyl)-(C_{1-5} alkyl), -(C_{0-4} alkylene)-SO_2-NH_2, -(C_{0-4} alkylene)-SO_2-NH(C_{1-5} alkyl), -(C_{0-4} alkylene)-SO_2-N(C_{1-5} alkyl)(C_{1-5} alkyl), -(C_{0-4} alkylene)-NH-SO_2-(C_{1-5} alkyl), -(C_{0-4} alkylene)-N(C_{1-5} alkyl)-SO_2-(C_{1-5} alkyl), -(C_{0-4} alkylene)-SO_2-(C_{1-5}

alkyl), -(C_{0-4} alkylene)-SO-(C_{1-5} alkyl), -(C_{0-4} alkylene)-carbocyclyl, and -(C_{0-4} alkylene)-heterocyclyl, wherein the carbocyclyl moiety in said -(C_{0-4} alkylene)-carbocyclyl and the heterocyclyl moiety in said -(C_{0-4} alkylene)-heterocyclyl are each optionally substituted with one or more groups R^{Cyc}; and

each R^{Cyc} is independently selected from C_{1-5} alkyl, C_{2-5} alkenyl, C_{2-5} alkynyl, -(C_{0-4} alkylene)-OH, -(C_{0-4} alkylene)-O(C_{1-5} alkyl), -(C_{0-4} alkylene)-O(C_{1-5} alkylene)-OH, -(C_{0-4} alkylene)-O(C_{1-5} alkylene)-O(C_{1-5} alkyl), -(C_{0-4} alkylene)-SH, -(C_{0-4} alkylene)-S(C_{1-5} alkyl), -(C_{0-4} alkylene)-NH_2, -(C_{0-4} alkylene)-NH(C_{1-5} alkyl), -(C_{0-4} alkylene)-N(C_{1-5} alkyl)(C_{1-5} alkyl), -(C_{0-4} alkylene)-NH-OH, -(C_{0-4} alkylene)-N(C_{1-5} alkyl)-OH, -(C_{0-4} alkylene)-NH-O(C_{1-5} alkyl), -(C_{0-4} alkylene)-N(C_{1-5} alkyl)-O(C_{1-5} alkyl), halogen, C_{1-5} haloalkyl, -(C_{0-4} alkylene)-O-(C_{1-5} haloalkyl), -(C_{0-4} alkylene)-CN, -(C_{0-4} alkylene)-CHO, -(C_{0-4} alkylene)-CO-(C_{1-5} alkyl), -(C_{0-4} alkylene)-COOH, -(C_{0-4} alkylene)-CO-O-(C_{1-5} alkyl), -(C_{0-4} alkylene)-O-CO-(C_{1-5} alkyl), -(C_{0-4} alkylene)-CO-NH_2, -(C_{0-4} alkylene)-CO-NH(C_{1-5} alkyl), -(C_{0-4} alkylene)-CO-N(C_{1-5} alkyl)(C_{1-5} alkyl), -(C_{0-4} alkylene)-NH-CO-(C_{1-5} alkyl), -(C_{0-4} alkylene)-N(C_{1-5} alkyl)-CO-(C_{1-5} alkyl), -(C_{0-4} alkylene)-NH-CO-O-(C_{1-5} alkyl), -(C_{0-4} alkylene)-N(C_{1-5} alkyl)-CO-O-(C_{1-5} alkyl), -(C_{0-4} alkylene)-O-CO-NH-(C_{1-5} alkyl), -(C_{0-4} alkylene)-O-CO-N(C_{1-5} alkyl)-(C_{1-5} alkyl), -(C_{0-4} alkylene)-SO_2-NH_2, -(C_{0-4} alkylene)-SO_2-NH(C_{1-5} alkyl), -(C_{0-4} alkylene)-SO_2-N(C_{1-5} alkyl)(C_{1-5} alkyl), -(C_{0-4} alkylene)-NH-SO_2-(C_{1-5} alkyl), -(C_{0-4} alkylene)-N(C_{1-5} alkyl)-SO_2-(C_{1-5} alkyl), -(C_{0-4} alkylene)-SO_2-(C_{1-5} alkyl), and -(C_{0-4} alkylene)-SO-(C_{1-5} alkyl);

or a pharmaceutically acceptable salt or solvate thereof;

for use in the treatment or prevention of a fragile X associated disorder.

2. The compound for use according to claim 1, wherein R^1 is C_{1-5} alkyl ; preferably wherein R^1 is methyl.

3. The compound for use according to any one of claims 1 or 2, wherein Z^1, Z^2 and Z^3 are each C(-R^6).

4. The compound for use according to any one of claims 1 to 3, wherein R^4 is halogen, $-CF_3$, or -CN, preferably wherein R^4 is -Cl.

5. The compound for use according to any one of claims 1 to 4, wherein each R^6 is independently selected from hydrogen, C_{1-5} alkyl, $-O(C_{1-5}$ alkyl), halogen, C_{1-5} haloalkyl, $-O-(C_{1-5}$ haloalkyl), and -CN, preferably wherein each R^6 is hydrogen.

6. The compound for use according to claim 1, wherein:
   - Z^1 and Z^3 are each $C(-R^6)$;
   - Z^2 is $C(-R^6)$ or N;
   - R^1 is selected from C_{1-5} alkyl, C_{2-5} alkenyl, $-(C_{0-4}$ alkylene)-CN, and $-(C_{1-4}$ alkylene)-COOH.

7. The compound for use according to claim 1, wherein:
   - Z^1, Z^2 and Z^3 are each $C(-R^6)$;
   - R^1 is C_{1-5} alkyl.

8. The compound for use according to claim 1, wherein:
   - Z^1 and Z^3 are each $C(-R^6)$;
   - Z^2 is $C(-R^6)$ or N.

9. The compound for use according to claim 1, wherein:
   - Z^1, Z^2 and Z^3 are each $C(-R^6)$;
   - R^1 is C_{1-5} alkyl.

10. The compound for use according to claim 1, wherein said compound is selected from:
    3-(5-chloro-2-methoxyphenyl)-3-methyl-6-(trifluoromethyl)indolin-2-one;
    3-(5-chloro-2-hydroxy-phenyl)-3-methyl-6-(trifluoromethyl)indolin-2-one;
    3-(5-chloro-2-methoxyphenyl)-3-ethyl-6-(trifluoromethyl)indolin-2-one;
    3-(5-chloro-2-methoxyphenyl)-3-propyl-6-(trifluoromethyl)indolin-2-one;
    3-benzyl-3-(5-chloro-2-methoxyphenyl)-6-(trifluoromethyl)indolin-2-one;
    2-(3-(5-chloro-2-methoxyphenyl)-2-oxo-6-(trifluoromethyl)indolin-3-yl)acetonitrile;
    3-allyl-3-(5-chloro-2-methoxyphenyl)-6-(trifluoromethyl)indolin-2-one;
    2-(3-(5-chloro-2-methoxyphenyl)-2-oxo-6-(trifluoromethyl)indolin-3-yl)acetic acid;

3-(2-chloro-5-methoxy-4-pyridyl)-3-methyl-6-(trifluoromethyl)indolin-2-one;
3-(3-methoxy-4-pyridyl)-3-methyl-6-(trifluoromethyl)indolin-2-one;
3-[2-methoxy-5-(1-methylimidazol-2-yl)phenyl]-3-methyl-6-(trifluoromethyl)indolin-2-one;
3-(5-chloro-2-methoxy-phenyl)-6-(difluoromethyl)-3-methyl-indolin-2-one;
3-(5-chloro-2-methoxy-3-pyridyl)-3-methyl-6-(trifluoromethyl)indolin-2-one;
6-chloro-3-(5-chloro-2-methoxyphenyl)-3-methylindolin-2-one;
6-chloro-3-(2-chloro-5-methoxypyridin-4-yl)-3-methylindolin-2-one;
3-(6-chloro-3-methoxypyridin-2-yl)-3-methyl-6-(trifluoromethyl)indolin-2-one;
6-chloro-3-(5-chloro-2-methoxypyridin-3-yl)-3-methylindolin-2-one;
6-chloro-3-(2-methoxy-5-(1-methyl-1H-imidazol-2-yl)phenyl)-3-methylindolin-2-one;
6-chloro-3-(6-chloro-3-methoxypyridin-2-yl)-3-methylindolin-2-one;
6-chloro-3-(2-methoxy-5-(1-methyl-1H-imidazol-2-yl)pyridin-3-yl)-3-methylindolin-2-one;
6-chloro-3-(5-methoxy-2-(1-methyl-1H-imidazol-2-yl)pyridin-4-yl)-3-methylindolin-2-one;
or a pharmaceutically acceptable salt or solvate thereof.

11. The compound for use according to claim 1, wherein said compound is 3-(5-chloro-2-methoxyphenyl)-3-methyl-6-(trifluoromethyl)indolin-2-one or a pharmaceutically acceptable salt or solvate thereof.

12. The compound for use according to claim 1, wherein said compound is (3R)-3-(5-chloro-2-methoxyphenyl)-3-methyl-6-(trifluoromethyl)indolin-2-one or a pharmaceutically acceptable salt or solvate thereof.

13. The compound for use according to any one of claims 1 to 12, wherein the fragile X associated disorder is selected from fragile X syndrome, fragile X-associated tremor/ataxia syndrome, fragile X-associated primary ovarian insufficiency, fragile X-associated polycystic ovarian syndrome, and fragile XE-associated mental retardation; preferably wherein the fragile X associated disorder is fragile X syndrome.

14. *In vitro* use of a compound as defined in any one of claims 1 to 12 as a maxi-K potassium channel opener.

15. A compound of formula (Ia)



(Ia)

wherein:

R^1 is selected from C_{1-5} alkyl, C_{2-5} alkenyl, benzyl, -(C_{0-4} alkylene)-CN, and -(C_{1-4} alkylene)-COOH, and R^5 is a group R^{5A};

R^2 is hydrogen;

ring A is phenyl which is fused to the ring containing -CO-NR^2-;

each R^3 is halogen or C_{1-5} haloalkyl ;

n is 1, 2, 3 or 4;

one of the ring atoms Z^1, Z^2 and Z^3 is C(-R^6) or N, and the other two of said ring atoms are each C(-R^6);

R^4 is selected from hydrogen, C_{1-5} alkyl, C_{2-5} alkenyl, C_{2-5} alkynyl, -(C_{0-4} alkylene)-OH, -(C_{0-4} alkylene)-O(C_{1-5} alkyl), -(C_{0-4} alkylene)-O(C_{1-5} alkylene)-OH, -(C_{0-4} alkylene)-O(C_{1-5} alkylene)-O(C_{1-5} alkyl), -(C_{0-4} alkylene)-SH, -(C_{0-4} alkylene)-S(C_{1-5} alkyl), -(C_{0-4} alkylene)-NH_2, -(C_{0-4} alkylene)-NH(C_{1-5} alkyl), -(C_{0-4} alkylene)-N(C_{1-5} alkyl)(C_{1-5} alkyl), -(C_{0-4} alkylene)-NH-OH, -(C_{0-4} alkylene)-N(C_{1-5} alkyl)-OH, -(C_{0-4} alkylene)-NH-O(C_{1-5} alkyl), -(C_{0-4} alkylene)-N(C_{1-5} alkyl)-O(C_{1-5} alkyl), halogen, C_{1-5} haloalkyl, -(C_{0-4} alkylene)-O-(C_{1-5} haloalkyl), -(C_{0-4} alkylene)-CN, -(C_{0-4} alkylene)-CHO, -(C_{0-4} alkylene)-CO-(C_{1-5} alkyl), -(C_{0-4} alkylene)-COOH, -(C_{0-4} alkylene)-CO-O-(C_{1-5} alkyl), -(C_{0-4} alkylene)-O-CO-(C_{1-5} alkyl), -(C_{0-4} alkylene)-CO-NH_2, -(C_{0-4} alkylene)-CO-NH(C_{1-5} alkyl), -(C_{0-4} alkylene)-CO-N(C_{1-5} alkyl)(C_{1-5} alkyl), -(C_{0-4}

alkylene)-NH-CO-(C_{1-5} alkyl), -(C_{0-4} alkylene)-N(C_{1-5} alkyl)-CO-(C_{1-5} alkyl), -(C_{0-4} alkylene)-NH-CO-O-(C_{1-5} alkyl), -(C_{0-4} alkylene)-N(C_{1-5} alkyl)-CO-O-(C_{1-5} alkyl), -(C_{0-4} alkylene)-O-CO-NH-(C_{1-5} alkyl), -(C_{0-4} alkylene)-O-CO-N(C_{1-5} alkyl)-(C_{1-5} alkyl), -(C_{0-4} alkylene)-SO_2-NH_2, -(C_{0-4} alkylene)-SO_2-NH(C_{1-5} alkyl), -(C_{0-4} alkylene)-SO_2-N(C_{1-5} alkyl)(C_{1-5} alkyl), -(C_{0-4} alkylene)-NH-SO_2-(C_{1-5} alkyl), -(C_{0-4} alkylene)-N(C_{1-5} alkyl)-SO_2-(C_{1-5} alkyl), -(C_{0-4} alkylene)-SO_2-(C_{1-5} alkyl), -(C_{0-4} alkylene)-SO-(C_{1-5} alkyl), -(C_{0-4} alkylene)-carbocyclyl, and -(C_{0-4} alkylene)-heterocyclyl, wherein the carbocyclyl moiety in said -(C_{0-4} alkylene)-carbocyclyl and the heterocyclyl moiety in said -(C_{0-4} alkylene)-heterocyclyl are each optionally substituted with one or more groups R^{Cyc};

R^{5A} is selected from-OH and -O(C_{1-5} alkyl);

each R^6 is independently selected from hydrogen, C_{1-5} alkyl, C_{2-5} alkenyl, C_{2-5} alkynyl, -(C_{0-4} alkylene)-OH, -(C_{0-4} alkylene)-O(C_{1-5} alkyl), -(C_{0-4} alkylene)-O(C_{1-5} alkylene)-OH, -(C_{0-4} alkylene)-O(C_{1-5} alkylene)-O(C_{1-5} alkyl), -(C_{0-4} alkylene)-SH, -(C_{0-4} alkylene)-S(C_{1-5} alkyl), -(C_{0-4} alkylene)-NH_2, -(C_{0-4} alkylene)-NH(C_{1-5} alkyl), -(C_{0-4} alkylene)-N(C_{1-5} alkyl)(C_{1-5} alkyl), -(C_{0-4} alkylene)-NH-OH, -(C_{0-4} alkylene)-N(C_{1-5} alkyl)-OH, -(C_{0-4} alkylene)-NH-O(C_{1-5} alkyl), -(C_{0-4} alkylene)-N(C_{1-5} alkyl)-O(C_{1-5} alkyl), halogen, C_{1-5} haloalkyl, -(C_{0-4} alkylene)-O-(C_{1-5} haloalkyl), -(C_{0-4} alkylene)-CN, -(C_{0-4} alkylene)-CHO, -(C_{0-4} alkylene)-CO-(C_{1-5} alkyl), -(C_{0-4} alkylene)-COOH, -(C_{0-4} alkylene)-CO-O-(C_{1-5} alkyl), -(C_{0-4} alkylene)-O-CO-(C_{1-5} alkyl), -(C_{0-4} alkylene)-CO-NH_2, -(C_{0-4} alkylene)-CO-NH(C_{1-5} alkyl), -(C_{0-4} alkylene)-CO-N(C_{1-5} alkyl)(C_{1-5} alkyl), -(C_{0-4} alkylene)-NH-CO-(C_{1-5} alkyl), -(C_{0-4} alkylene)-N(C_{1-5} alkyl)-CO-(C_{1-5} alkyl), -(C_{0-4} alkylene)-NH-CO-O-(C_{1-5} alkyl), -(C_{0-4} alkylene)-N(C_{1-5} alkyl)-CO-O-(C_{1-5} alkyl), -(C_{0-4} alkylene)-O-CO-NH-(C_{1-5} alkyl), -(C_{0-4} alkylene)-O-CO-N(C_{1-5} alkyl)-(C_{1-5} alkyl), -(C_{0-4} alkylene)-SO_2-NH_2, -(C_{0-4} alkylene)-SO_2-NH(C_{1-5} alkyl), -(C_{0-4} alkylene)-SO_2-N(C_{1-5} alkyl)(C_{1-5} alkyl), -(C_{0-4} alkylene)-NH-SO_2-(C_{1-5} alkyl), -(C_{0-4} alkylene)-N(C_{1-5} alkyl)-SO_2-(C_{1-5} alkyl), -(C_{0-4} alkylene)-SO_2-(C_{1-5} alkyl), -(C_{0-4} alkylene)-SO-(C_{1-5} alkyl), -(C_{0-4} alkylene)-carbocyclyl, and -(C_{0-4} alkylene)-heterocyclyl, wherein the carbocyclyl moiety in said -(C_{0-4} alkylene)-carbocyclyl and the heterocyclyl moiety in said -(C_{0-4} alkylene)-heterocyclyl are each optionally substituted with one or more groups R^{Cyc}; and

each R^{Cyc} is independently selected from C_{1-5} alkyl, C_{2-5} alkenyl, C_{2-5} alkynyl, -(C_{0-4} alkylene)-OH, -(C_{0-4} alkylene)-O(C_{1-5} alkyl), -(C_{0-4} alkylene)-O(C_{1-5} alkylene)-OH, -(C_{0-4} alkylene)-O(C_{1-5} alkylene)-O(C_{1-5} alkyl), -(C_{0-4} alkylene)-SH, -(C_{0-4} alkylene)-S(C_{1-5} alkyl), -(C_{0-4} alkylene)-NH_2, -(C_{0-4} alkylene)-NH(C_{1-5} alkyl), -(C_{0-4} alkylene)-N(C_{1-5} alkyl)(C_{1-5} alkyl), -(C_{0-4} alkylene)-NH-OH, -(C_{0-4} alkylene)-N(C_{1-5} alkyl)-OH, -(C_{0-4} alkylene)-NH-O(C_{1-5} alkyl), -(C_{0-4} alkylene)-N(C_{1-5} alkyl)-O(C_{1-5} alkyl), halogen, C_{1-5} haloalkyl, -(C_{0-4} alkylene)-O-(C_{1-5} haloalkyl), -(C_{0-4} alkylene)-CN, -(C_{0-4} alkylene)-CHO, -(C_{0-4} alkylene)-CO-(C_{1-5} alkyl), -(C_{0-4} alkylene)-COOH, -(C_{0-4} alkylene)-CO-O-(C_{1-5} alkyl), -(C_{0-4} alkylene)-O-CO-(C_{1-5} alkyl), -(C_{0-4} alkylene)-CO-NH_2, -(C_{0-4} alkylene)-CO-NH(C_{1-5} alkyl), -(C_{0-4} alkylene)-CO-N(C_{1-5} alkyl)(C_{1-5} alkyl), -(C_{0-4} alkylene)-NH-CO-(C_{1-5} alkyl), -(C_{0-4} alkylene)-N(C_{1-5} alkyl)-CO-(C_{1-5} alkyl), -(C_{0-4} alkylene)-NH-CO-O-(C_{1-5} alkyl), -(C_{0-4} alkylene)-N(C_{1-5} alkyl)-CO-O-(C_{1-5} alkyl), -(C_{0-4} alkylene)-O-CO-NH-(C_{1-5} alkyl), -(C_{0-4} alkylene)-O-CO-N(C_{1-5} alkyl)-(C_{1-5} alkyl), -(C_{0-4} alkylene)-SO_2-NH_2, -(C_{0-4} alkylene)-SO_2-NH(C_{1-5} alkyl), -(C_{0-4} alkylene)-SO_2-N(C_{1-5} alkyl)(C_{1-5} alkyl), -(C_{0-4} alkylene)-NH-SO_2-(C_{1-5} alkyl), -(C_{0-4} alkylene)-N(C_{1-5} alkyl)-SO_2-(C_{1-5} alkyl), -(C_{0-4} alkylene)-SO_2-(C_{1-5} alkyl), and -(C_{0-4} alkylene)-SO-(C_{1-5} alkyl);

or a pharmaceutically acceptable salt or solvate thereof;

wherein if n is 1 or 2, then at least one group R^3 is different from halogen.

16. The compound of claim 15, wherein said compound is selected from:
3-(5-chloro-2-methoxyphenyl)-3-methyl-6-(trifluoromethyl)indolin-2-one;
3-(5-chloro-2-hydroxy-phenyl)-3-methyl-6-(trifluoromethyl)indolin-2-one;
3-(5-chloro-2-methoxyphenyl)-3-ethyl-6-(trifluoromethyl)indolin-2-one;
3-(5-chloro-2-methoxyphenyl)-3-propyl-6-(trifluoromethyl)indolin-2-one;
3-benzyl-3-(5-chloro-2-methoxyphenyl)-6-(trifluoromethyl)indolin-2-one;
2-(3-(5-chloro-2-methoxyphenyl)-2-oxo-6-(trifluoromethyl)indolin-3-yl)acetonitrile;
3-allyl-3-(5-chloro-2-methoxyphenyl)-6-(trifluoromethyl)indolin-2-one;
2-(3-(5-chloro-2-methoxyphenyl)-2-oxo-6-(trifluoromethyl)indolin-3-yl)acetic acid;
3-(2-chloro-5-methoxy-4-pyridyl)-3-methyl-6-(trifluoromethyl)indolin-2-one;
3-(3-methoxy-4-pyridyl)-3-methyl-6-(trifluoromethyl)indolin-2-one;

3-[2-methoxy-5-(1-methylimidazol-2-yl)phenyl]-3-methyl-6-(trifluoromethyl)indolin-2-one;
3-(5-chloro-2-methoxy-phenyl)-6-(difluoromethyl)-3-methyl-indolin-2-one;
3-(5-chloro-2-methoxy-3-pyridyl)-3-methyl-6-(trifluoromethyl)indolin-2-one;
3-(6-chloro-3-methoxypyridin-2-yl)-3-methyl-6-(trifluoromethyl)indolin-2-one;
or a pharmaceutically acceptable salt or solvate thereof.

17. The compound of claim 15, wherein said compound is 3-(5-chloro-2-methoxyphenyl)-3-methyl-6-(trifluoromethyl)indolin-2-one or a pharmaceutically acceptable salt or solvate thereof.

18. The compound of claim 15, wherein said compound is (3R)-3-(5-chloro-2-methoxyphenyl)-3-methyl-6-(trifluoromethyl)indolin-2-one or a pharmaceutically acceptable salt or solvate thereof.

19. The compound of any one of claims 15 to 18 for use as a medicament.

20. The compound of any one of claims 15 to 18 for use in the treatment or prevention of a disease/disorder selected from stroke, ischemia reperfusion injury, ischemic heart disease, hypertension, myocardial infarction, allergic rhinitis, asthma, chronic obstructive pulmonary disease, multiple sclerosis, spasticity, tremor, a muscular disorder, dyskinesia, bladder dysfunction, overactive bladder, urinary incontinence, irritable bowel syndrome, faecal incontinence, constipation, gastro-oesophageal reflux disorder, impaired gastrointenstinal passage, detrusor underactivity, erectile dysfunction, opioid-induced respiratory depression, anxiety, an anxiety disorder, sensory processing disorder, autism, an autism spectrum disorder, a social or pragmatic communication disorder, attention deficit hyperactivity disorder, social phobia, intellectual disability, pain, epilepsy, an epilepsy and/or seizure disorder, Dravet syndrome, generalized epilepsy and paroxysmal dyskinesia, temporal lobe epilepsy, psychosis, schizophrenia, negative symptoms of schizophrenia, cognitive impairment in schizophrenia, Phelan-McDermid syndrome, Rett syndrome, Pitt-Hopkins syndrome, 16p11.2 deletion syndrome, Williams-Beuren syndrome, open-angle ocular hypertension, glaucoma, tinnitus, diabetic retinopathy, tocolysis, migraine, Liang-Wang syndrome, Smith-Lemli-Opitz syndrome, Angelman syndrome, and Hutchinson-Gilford progeria syndrome.